Hopp til hovedinnhold

Føflekkreft - tilbake til hverdagen

For mange av dem som behandles for føflekkreft, er de praktiske konsekvensene små. Svulsten fjernes med et forholdsvis lite inngrep, og man trenger ikke legges inn på sykehus. Sykmelding er ofte heller ikke nødvendig. På mange måter går livet videre som om ingenting var skjedd.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/kreft/hud-kreft/hudkreft-tilbake-til-hverdagen/ 

Oppfølging og kontroll

Selvundersøkelse

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Malignt melanom. Referanselisten for dette dokumentet vises nedenfor.

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer. Helsedirektoratet, sist oppdatert mai 2020. www.helsedirektoratet.no 
  2. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020. www.kreftregisteret.no 
  3. Ferlay J, Ervik M, Lam F et al. (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed 21 Apr 2022. Available from: gco.iarc.fr 
  4. Årsrapport 2018: Resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for melanom. Oslo: Kreftregisteret, 2019. ISBN: 978-82-473-0071-8 www.kreftregisteret.no 
  5. Kottschade LA, Grotz TE, Dronca RS et al. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol 2014; 37: 635-41. pmid:23563206 PubMed 
  6. Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: A cohort study. Cancer Epidemiol Biomarkers Prev 2014; 23: 1080. pmid: 24876226 PubMed 
  7. Keim U, Gandini S, Amaral T et al. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. Eur J Cancer. 2021 Dec;159:98-104. Epub 2021 Nov 3. PMID: 34742161. PubMed 
  8. Pampena R, Kyrgidis A, Lallas A, et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938-45. pmid:28864306 PubMed 
  9. Vourc'h-Jourdain M1, Martin L, Barbarot S. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68(3): 493-8. pmid:23182059 PubMed 
  10. Reddy KK, Farber MJ, Bhawan J et al. Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatol 2013; 149: 928-34. pmid:23760581 PubMed 
  11. Ribero S, Zugna D, Osella-Abate S, et al. Prediction of high naevus count in a healthy UK population to estimate melanoma risk. Br J Dermatol 2015. pmid: 26479165 PubMed 
  12. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008955. pmid: 23775773 PubMed 
  13. Chen T, Fallah M, Försti A et al. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas. JAMA Dermatol 2015; 151: 607. pmid:25671687 PubMed 
  14. Wu S, Cho E, Li W et al. History of Severe Sunburn and Risk of Skin Cancer Among Women and Men in 2 Prospective Cohort Studies. Am J Epidemiol 2016; 183(9): 824-33. pmid:27045074 PubMed 
  15. Gandini S, Doré JF, Autier P et al. Epidemiological evidence of carcinogenicity of sunbed use and of efficacy of preventive measures. J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:57-62. PMID: 30811691. PubMed 
  16. Gaudy-Marqueste C, Wazaefi Y, Bruneu Y et al. Ugly Duckling Sign as a Major Factor of Efficiency in Melanoma Detection. JAMA Dermatol 2017; 153: 279-84. pmid:28196213 PubMed 
  17. Bhatt M, Nabatian A, Kriegel D, Khorasani H. Does an increased number of moles correlate to a higher risk of melanoma? Melanoma Manag. 2016 Jun;3(2):85-87. Epub 2016 May 19. PMID: 30190875 PubMed 
  18. American Academy of Dermatology Ad Hoc Task Force for the ABCDEs of Melanoma. Early detection of melanoma: reviewing the ABCDEs. J Am Acad Dermatol. 2015 ;72(4):717-23. pmid: 25698455 PubMed 
  19. Williams NM, Rojas KD, Reynolds JM et al. Assessment of Diagnostic Accuracy of Dermoscopic Structures and Patterns Used in Melanoma Detection: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021 Aug 4. Epub ahead of print. PMID: 34347005. PubMed 
  20. Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD010308. pmid: 25526608 PubMed 
  21. Utjés D, Malmstedt J, Teras J et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet 2019; 394: 471-77. pmid:31280965 PubMed 
  22. Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, Stratigos A. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD010307. DOI: 10.1002/14651858.CD010307.pub2. The Cochrane Library 
  23. Hao C, Tian J, Liu H et al. Efficacy and Safety of anti-PD-1 and anti-PD-1 Combined With anti-CTLA-4 Immunotherapy to Advanced Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) 2017; 96: E7325. pmid:28658143 PubMed 
  24. Larkin J, Chiarion-Seleni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015. pmid: 26027431 PubMed 
  25. Long GV, Atkinson V, Lo S et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672-81. pmid:29602646 PubMed 
  26. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 May;16(5):522-30. pmid: 25840693 PubMed 
  27. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375(19): 1845-55. pmid:27717298 PubMed 
  28. Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD011123. DOI: 10.1002/14651858.CD011123.pub2. The Cochrane Library 
  29. Long GV, Hauschild A, Santinami M et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377: 1813-23. pmid:28891408 PubMed 
  30. Spasojevic M, Mariathasan AB, Frich L et al.. Kreftbehandling med isolert ekstremitetsperfusjon. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.21.0194 DOI 
  31. Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585: 107-12. pmid:32728218 PubMed 
  32. Wernli KJ, Henrikson NB, Morrison CC etal. Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 316: 436-47. pmid:27458949 PubMed 
  33. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD012352. DOI: 10.1002/14651858.CD012352.pub2. Accessed 21 April 2022. The Cochrane Library 
  34. Matsumoto M, Wack S, Weinstock MAet al. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. 2022 Apr 6:e220253. Epub ahead of print. PMID: 35385051 PubMed 
  35. O'Shea SJ, Davies JR, Newton-Bishop JA. Vitamin D, vitamin A, the primary melanoma transcriptome and survival. Br J Dermatol 2016; 175: 30-4. pmid:27667313 PubMed 
  36. Diehl JW, Chiu MW. Effects of ambient sunlight and photoprotection on vitamin D status. Dermatol Ther 2010; 23: 48-60. pmid:20136908 PubMed 
  37. Calomarde-Rees L, García-Calatayud R, Requena Caballero C et al. Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. JAMA Dermatol 2019.0069. pmid:31042264 PubMed 
  38. Green AC, Baade P, Coory M et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30(13): 1462. pmid:22412152 PubMed